These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22054762)

  • 21. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks.
    Wallis RS
    Lancet Infect Dis; 2008 Oct; 8(10):601-11. PubMed ID: 18922482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tuberculosis in patients treated with tumor necrosis factor-alpha antagonists living in an endemic area. Is the risk worthwhile?
    Rojas-Villarraga A; Agudelo CA; Pineda-Tamayo R; Porras A; Matute G; Anaya JM
    Biomedica; 2007 Jun; 27(2):159-71. PubMed ID: 17713627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatosplenic T-cell lymphomas and therapy with TNF-alpha-blocking biologics: a risk for psoriasis patients?
    Beyer M; Steinhoff M; Anagnostopoulos I; Assaf C; Sterry W
    J Dtsch Dermatol Ges; 2009 Mar; 7(3):191-4. PubMed ID: 19192165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How to manage infections in the era of biologics?
    Saraceno R; Chimenti S
    Dermatol Ther; 2008; 21(3):180-6. PubMed ID: 18564248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse effects of biological agents in the treatment of psoriasis.
    Rongioletti F; Burlando M; Parodi A
    Am J Clin Dermatol; 2010; 11 Suppl 1():35-7. PubMed ID: 20586505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pulmonary infectious complications of tumor necrosis factor blockade.
    Wallis RS; Schluger NW
    Infect Dis Clin North Am; 2010 Sep; 24(3):681-92. PubMed ID: 20674798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry.
    Pérez-Sola MJ; Torre-Cisneros J; Pérez-Zafrilla B; Carmona L; Descalzo MA; Gómez-Reino JJ;
    Med Clin (Barc); 2011 Nov; 137(12):533-40. PubMed ID: 21514606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prevention of infections in patients with inflammatory bowel disease during TNF inhibitor treatment].
    Christensen KR; Steenholdt C
    Ugeskr Laeger; 2014 Nov; 176(48):. PubMed ID: 25430572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe.
    Zanger P; Kötter I; Kremsner PG; Gabrysch S
    Clin Microbiol Infect; 2012 Jul; 18(7):670-6. PubMed ID: 21985586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biologic therapy and risk of infection.
    Gordon R; Mays R; Doan H; Lapolla W; Tyring SK
    Skin Therapy Lett; 2012 Apr; 17(4):1-4. PubMed ID: 22491803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TNF-inhibitors in Wegener's granulomatosis.
    Lamprecht P; Voswinkel J; Gross WL
    Kidney Blood Press Res; 2005; 28(1):62. PubMed ID: 15557770
    [No Abstract]   [Full Text] [Related]  

  • 32. Tumor necrosis factor inhibitors and infection complications.
    Crawford M; Curtis JR
    Curr Rheumatol Rep; 2008 Oct; 10(5):383-9. PubMed ID: 18817643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Morphea, an unusual side effect of anti-TNF-alpha treatment.
    Mattozzi C; Richetta AG; Cantisani C; Giancristoforo S; D'Epiro S; Gonzalez Serva A; Viola F; Cucchiara S; Calvieri S
    Eur J Dermatol; 2010; 20(3):400-1. PubMed ID: 20299314
    [No Abstract]   [Full Text] [Related]  

  • 34. [Tumor necrosis factor blocking agents: a review. Part II: safety and recommendations].
    Rodríguez Moreno C; López Vázquez P; Durán Parrondo C; Tato Herrero F; Lado Lado F; Velasco González M
    An Med Interna; 2006 Feb; 23(2):86-92. PubMed ID: 16566659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Uncovering the risks of immunosuppressive therapy in patients with uveitis.
    Goldstein DA
    Arch Ophthalmol; 2009 Jun; 127(6):799-800. PubMed ID: 19506201
    [No Abstract]   [Full Text] [Related]  

  • 36. Anti-TNF-alpha therapy for orofacial granulomatosis: proceed with caution.
    Gaya DR; Aitken S; Fennell J; Satsangi J; Shand AG
    Gut; 2006 Oct; 55(10):1524-5. PubMed ID: 16966709
    [No Abstract]   [Full Text] [Related]  

  • 37. Mycobacterial disease attributable to tumor necrosis factor-alpha blockers.
    Wallis RS
    Clin Infect Dis; 2008 Dec; 47(12):1603-5; author reply 1605-6. PubMed ID: 19025369
    [No Abstract]   [Full Text] [Related]  

  • 38. Safety of biologics: current issues and future concerns.
    Feagan BG
    Acta Gastroenterol Belg; 2001; 64(2):210-4. PubMed ID: 11475138
    [No Abstract]   [Full Text] [Related]  

  • 39. Anti-tumor necrosis factor-alpha in asthma.
    Krouwels FH
    Am J Respir Crit Care Med; 2007 Feb; 175(3):288; author reply 288-9. PubMed ID: 17234910
    [No Abstract]   [Full Text] [Related]  

  • 40. Respiratory infections associated with anti-TNFα agents.
    Blanchard E; Truchetet ME; Machelart I; Séneschal J; Raherison-Semjen C
    Med Mal Infect; 2017 Oct; 47(6):375-381. PubMed ID: 28602386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.